Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, CT, USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.

Triple negative breast cancer is so called because it lacks molecular characteristics that are associated with response to modern targeted treatments. Hatzis and colleagues selected individual tumors from patients who had exhibited either good or poor sensitivity to cytotoxic chemotherapy, and characterized 29 cases of the disease by whole exome sequencing, with validation in further groups of patients. Patients with a newly-defined "BRCA deficient" subtype experienced better survival with chemotherapy, and had a higher burden of mutations and neoantigens that could be targeted by the immune system. Based on these findings, the authors suggest that immunotherapies might be tested in patients with BRCA deficient, triple negative breast cancer.

In a commissioned Perspective article, Mack Su and David Fisher of Massachusetts General Hospital, Boston, MA, USA discuss developments in cancer immunotherapy, an area which has had a long history. During the past decade there have been notable advances in the treatment of melanoma, an aggressive tumor type which is increasing in incidence in some populations. Alongside development of drugs which target the BRAF mutations that are common in melanoma, therapies have been discovered that stimulate the immune response to tumors--blocking so-called checkpoints, or inhibitors of the immune response. Su and Fisher describe the potential for use of different combinations of immune and targeted therapies and conclude that, as new immunotherapies are developed and tested in different tumor types, "deeper mechanistic insight will be required to inform clinical decisions."

Department of Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America MTA TTK Lendulet Cancer Biomarker Research Group, Research Center for Natural Sciences, Budapest, Hungary 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary Department of Genetics, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Yale Cancer Center, New Haven, Connecticut, United States of America

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

The authors gratefully acknowledge support from NIH grants 5P01 CA163222, 5R01 AR043369-19, and T32GM007753, and grants from the Melanoma Research Alliance, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Personalizing chemotherapy to treat pediatric leukemiaA team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.

How gut microbes help chemotherapy drugsTwo bacterial species that inhabit the human gut activate immune cells to boost the effectiveness of a commonly prescribed anticancer drug, researchers report Oct.

Dialing up chemotherapy for pancreatic cancer with ultrasoundResearchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.

#514 Arctic Energy (Rebroadcast)This week we're looking at how alternative energy works in the arctic. We speak to Louie Azzolini and Linda Todd from the Arctic Energy Alliance, a non-profit helping communities reduce their energy usage and transition to more affordable and sustainable forms of energy. And the lessons they're learning along the way can help those of us further south.